# Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

> **NCT01720407** · PHASE3 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 259 (actual)

## Conditions studied

- Lentigo Maligna Melanoma (Head or Neck)

## Interventions

- **DRUG:** Imiquimod cream + surgery
- **DRUG:** Placebo + surgery

## Key facts

- **NCT ID:** NCT01720407
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2019-10
- **Final completion:** 2022-11-10
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2022-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01720407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01720407, "Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01720407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*